Tag archive for ‘Astellas’
Cytokinetics: Another Positive Deal for Shareholders, This Time with Astellas (CYTK, $11.81)
Cytokinetics (CYTK) has completed its second meaningful deal in two weeks. Today they announced a deal with Astellas (ALPMY) and on June 12, they announced a deal that allows Amgen to develop omecamtiv mecarbil in Japan. Today’s deal brings in $16 million as an upfront milestone and the Amgen (AMGN) deal brought in $15 million […]